We are doing this study to find out if an experimental drug called RMC-6236 (the study drug) is a safe and effective option for people with metastatic pancreatic ductal adenocarcinoma (PDAC). We want to see how well the study drug works compared to the standard chemotherapy regimen for PDAC.

Pancreatic Ductal Adenocarcinoma (PDAC)

Adults ages 18+ who:

• Are diagnosed with PDAC, including adenosquamous carcinoma and poorly differentiated carcinoma
• Have confirmed metastases (evidence that the cancer has spread)

For more information, please contact the study team at dana.a.warren@duke.edu.

If you choose to join this study, you will get a random assignment (like a coin flip) to either:

• Get the study drug, which is a pill that you take once per day; OR
• Get whatever standard chemotherapy option the study doctor believes will be most beneficial for you

Participation in this study will last for up to 3 years.